Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited third quarterly report for 2025, covering the period ending on September 30. The report is prepared in accordance with PRC Accounting Standards and assures stakeholders of its accuracy and completeness, as warranted by the company’s board and senior management.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical industry. The company, along with its subsidiaries, is involved in the development, manufacturing, and distribution of pharmaceutical products.
Average Trading Volume: 10,511,559
Technical Sentiment Signal: Buy
Current Market Cap: HK$80.2B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.